Dr. Landovitz received his medical degree from the Harvard School of Medicine (Boston, Massachusetts, USA). Following this, he completed an internship and residency in Internal Medicine at Brigham and Women’s Hospital (Boston, Massachusetts, USA) and an Infectious Diseases fellowship with Brigham and Women’s Hospital and Massachusetts General Hospital (Boston, Massachusetts, USA). He served as Medical Co-Director of the Vietnam-CDC-Harvard Medical School-AIDS-Partnership (VCHAP), helping to train Vietnamese physicians in HIV care and treatment. In 2006 he joined the UCLA Center for Clinical AIDS Research and Education (CARE), where he now holds numerous positions of responsibility. As an infectious disease and HIV clinician, his research interests include HIV prevention (including pre- and post-exposure prophylaxis and other combination prevention strategies) and the impact of such prevention interventions on risk behaviour. Dr. Landovitz is involved in many clinical trials, including the National Institutes of Health/Division of AIDS-funded Phase 2a and Phase 3 studies of long-acting injectable pre-exposure prophylaxis (PrEP) using cabotegravir. In 2010, he was awarded the John Carey Young Investigator Award by the AIDS Clinical Trials Group in 2010, and the American Association of HIV Medicine Research Award in 2017. Dr. Landovitz has authored over 100 publications, including articles in the journal AIDS, The New England Journal of Medicine, and the Journal of the American Medical Association.